a) an amino acid sequence of SEQ ID NO:1,

b) an amino acid sequence of SEQ ID NO:2, [3,or fragments thereof]

c) a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:1,

d) a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:2,

e) a biologically-active fragment of the amino acid sequence of SEQ ID NO:1,

f) an antigenically-active fragment of the amino acid sequence of SEQ ID NO:1,

g) a biologically-active fragment of the amino acid sequence of SEQ ID NO:2, and

h) an antigenically-active fragment of the amino acid sequence of SEQ ID NO:2.

2. (Once Amended.) A [substantially purified variant having at least 90% amino acid sequence identity to the sequence] polypeptide of claim 1 selected from the group consisting of:

(a) a polypeptide having at least 90% amino acid identity to SEQ ID NO:1 that retains at least one functional characteristic of the polypeptide of SEQ ID NO:1, and

(b) a polypeptide having at least 90% amino acid identity to SEQ ID NO:2 and which retains at least one functional characteristic of the polypeptide of SEQ ID NO:2.

14. (Once Amended.) A purified antibody which specifically binds to [the] a polypeptide of claim 1.

15. (Once Amended.) A purified agonist which specifically binds to and modulates the activity of [the] a polypeptide of claim 1.

16. (Once Amended.) A purified antagonist which specifically binds to and modulates the activity of [the] a polypeptide of claim 1.

17. (Reiterated.) A method for treating or preventing a neoplastic disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.

18. (Reiterated.) A method for treating or preventing a reproductive disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.

Please add the following new claims:

21. (New) A polypeptide of claim 1, having the amino acid sequence of SEQ ID NO:1 or SEQ ID NO: 2.

~~**22.** (New) A pharmaceutical composition comprising a polypeptide of claim 21 in conjunction with a suitable pharmaceutical carrier.~~

23. (New) An isolated polynucleotide selected from the group consisting of:

a) a polynucleotide sequence of SEQ ID NO:3

b) a polynucleotide sequence of SEQ ID NO:4,

c) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:3,

d) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:4 and

e) a polynucleotide sequence complementary to a), b), c) or d).

24. (New) A method of detecting a target polynucleotide in a sample, said target polynucleotide having the sequence of a polynucleotide of claim 23, comprising